Uterine Corpus Endometrial Stromal Sarcoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A uterine corpus sarcoma originating from the endometrial stroma. It is further subdivided into low grade and high grade endometrial stromal sarcoma. 
Uterine corpus endometrial stromal sarcomas most frequently harbor alterations in JAZF1, SUZ12, TSC2, PTEN, and CDKN2A .
JAZF1-SUZ12 Fusion, TSC2 Mutation, TP53 c.217-c.1178 Missense, TP53 Mutation, and TP53 Missense are the most common alterations in uterine corpus endometrial stromal sarcoma .
There is 1 clinical trial for uterine corpus endometrial stromal sarcoma, of which 1 is open and 0 are completed or closed. Of the trial that contains uterine corpus endometrial stromal sarcoma as an inclusion criterion, 1 is phase 2 (1 open).
MSI-Low and Microsatellite are the most frequent gene inclusion criteria for uterine corpus endometrial stromal sarcoma clinical trials .
Pembrolizumab is the most common intervention in uterine corpus endometrial stromal sarcoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.